Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Oral Biologics Market, By Drug Class (Glucagon-like Peptide 1 (GLP-1) Receptor Agonist, Hormone, Recombinant Enzyme, Guanylate Cyclase-C Agonist, Somatostatin Analogue, and Others), By Disease Indication (Diabetes, Hyperoxaluria, Acromegaly, Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC), and Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,437.4 million in 2021 and is expected to exhibit a CAGR of 35.3% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Increasing number of inorganic strategies such as collaborations, partnerships, mergers, and acquisitions by key players is a major factor driving the growth of the market.

In 2018, Amgen Inc., a biopharmaceutical company, entered in a deal with Entera Bio a biotechnologu Company, to develop oral formulations of biologics. As per the deal, Amgen gained access to Entera's technology to develop an oral formulation of a large molecule, as well as an option to develop two other (oral) large molecules.

In April 2018, Emisphere Technologies, Inc. amended its 2015 development and license agreement with Novo Nordisk A/S for development and commercialization of oral formulations of four classes of Novo Nordisk's investigational molecules targeting major metabolic disorders, including diabetes and obesity, using Emisphere's oral Eligen Technology.

Global Oral Biologics Market – Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic caused major disruptions to clinical trial execution in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced upheaval, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, CROs (contract research organization), and other organizations that support drug development shifted to remote working environments. An estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic.

Recently, the U.S. FDA guidance (March 2020 and updated July 2020) acknowledged that the impact of COVID-19 may require companies conducting clinical trials to consider virtual patient visits or put new processes in place of current protocols. Therefore, there are now more opportunities for using remote healthcare including conducting virtual or decentralized trials, site-less clinical trials, and use of other non-traditional approaches that do not involve in-person visits.

Browse 29 Market Data Tables and 36 Figures spread through 197 Pages and in-depth TOC on “Oral Biologics Market”- Global Forecast to 2028, By Drug Class (Glucagon-like Peptide 1 (GLP-1) Receptor Agonist, Hormone, Recombinant Enzyme, Guanylate Cyclase-C Agonist, Somatostatin Analogue, and Others), By Disease Indication (Diabetes, Hyperoxaluria, Acromegaly, Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC), and Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

To know the latest trends and insights prevalent in the Global Oral Biologics Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/oral-biologics-market-989

Key Takeaways of the Global Oral Biologics Market:

  • The global oral biologics market is expected to exhibit a CAGR of 35.3 % over the forecast period, owing to increasing incidences of diabetes is expected to drive the market growth over the forecast period. According to data published by the International Diabetes Federation, in 2017 around 425 million adults (aged 20 to 79 years) worldwide were living with diabetes, and the number is expected to increase to 629 million by 2045
  • Among Drug Class, Glucagon-like peptide-1 receptor agonists segment accounted for the largest market share in 2020, owing to increasing R&D. Key players including Novo Nordisk A/S and Oramed Pharmaceuticals, Inc. are involved in development of orally administered Glucagon-like Peptide 1 (GLP-1) Receptor Agonist. For instance, in March 2019, Novo Nordisk A/S submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for oral semaglutide, which is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in the form of a pill.
  • Key players operating in the global oral biologics market include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc., and Allena Pharmaceuticals, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.